This is an open-label, not controlled, sequential, dose escalation study of 16 weeks'
duration. The study is composed of two periods: a 0-2 week optional wash-out period depending
on previous antihypertensive treatment(s), followed by a 16-week open-label active treatment
period. Patients will be evaluated every 4 weeks during period 2. Treatment will start with
Aliskiren 150 mg with dose titration to Aliskiren 300 mg, and addition of HCTZ 12,5 mg and 25
if control of BP is not achieved (< 140/90 mmHg or 130/ 80 mmHg in diabetics patients). All
patients who have reached their BP target will be considered as having met the primary
endpoint and this visit will be considered as the final visit.